Search Page

1

Cite

Share

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Haanen JBAG, et al. Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225. Ann Oncol. 2017. PMID: 28881921 No abstract available.

Cite

Share

2

Cite

Share

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Gore ME, et al. Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.

Cite

Share

3

Cite

Share

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. van Erp NP, et al. J Clin Oncol. 2009 Sep 10;27(26):4406-12. doi: 10.1200/JCO.2008.21.7679. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667267

Cite

Share

4

Cite

Share

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE. Vermaat JS, et al. Ann Oncol. 2010 Jul;21(7):1472-1481. doi: 10.1093/annonc/mdp559. Epub 2009 Dec 18. Ann Oncol. 2010. PMID: 20022911

Cite

Share

5

Cite

Share

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.

Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boletti K, Sadev A, O'Brien T, Berney D, Beltran L, Haanen J, Bex A. Powles T, et al. Ann Oncol. 2011 May;22(5):1041-1047. doi: 10.1093/annonc/mdq564. Epub 2011 Jan 17. Ann Oncol. 2011. PMID: 21242586 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Cancer immunotherapy--revisited.

Lesterhuis WJ, Haanen JB, Punt CJ. Lesterhuis WJ, et al. Nat Rev Drug Discov. 2011 Aug 1;10(8):591-600. doi: 10.1038/nrd3500. Nat Rev Drug Discov. 2011. PMID: 21804596 Review.

Cite

Share

7

Cite

Share

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, Blank CU. Vogel WV, et al. J Clin Oncol. 2012 Jan 10;30(2):e7-e10. doi: 10.1200/JCO.2011.37.9693. Epub 2011 Nov 28. J Clin Oncol. 2012. PMID: 22124094 No abstract available.

Cite

Share

8

Cite

Share

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Ribas A, et al. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7. J Clin Oncol. 2013. PMID: 23295794 Free PMC article. Clinical Trial.

Cite

Share

9

Cite

Share

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.

Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A, Chowdhury S, Boleti E, Shamash J, Reynolds AR, Jones R, Blank C, Haanen J, Bex A. Powles T, et al. Ann Oncol. 2013 Aug;24(8):2098-103. doi: 10.1093/annonc/mdt130. Epub 2013 Apr 11. Ann Oncol. 2013. PMID: 23579815 Clinical Trial.

Cite

Share

10

Cite

Share

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, Hospers GA, Haanen JB, Kapiteijn E, Blank CU. Kelderman S, et al. Acta Oncol. 2013 Nov;52(8):1786-8. doi: 10.3109/0284186X.2013.786839. Epub 2013 Apr 23. Acta Oncol. 2013. PMID: 23607756 No abstract available.

Cite

Share